Grade Bio / Register / Entry 03 / Sheet G‑03.03
What this is
The sequence above is the identity: five residues, including two non‑proteinogenic ones, and a C‑terminal amide.
It is filled at 5 mg, sealed, as a white lyophilized solid. The molecular formula and the average mass are the figures the identity test is run against.
Specification
Every attribute below is checked against a fixed specification before a lot is released. The result column shows specimen lot L‑24309. A lot that misses a line is not released, and the register entry is marked rather than the sheet edited.
| Attribute | Method | Specification | Result |
|---|---|---|---|
| Appearance | Visual | White lyophilized solid | Conforms |
| Identity, mass | Mass confirmation | 711.85 g/mol (average) | Conforms |
| Assay, purity | RP‑HPLC | ≥ 98.0 % | Conforms |
| Presentation | Gravimetric | Lyophilized, 5 mg | Conforms |
Storage and retention
Documents behind this lot
| Document | No. | What it shows |
|---|---|---|
| Certificate of analysis | GB‑101 | Every attribute in table 2.1, the method, the specification and the measured result, signed on release. |
| Identity data package | GB‑104 | The reference data the lot's identity was confirmed against. |
| Method summary | GB‑110 | The analytical methods named in table 2.1, with their validation state. |
| Stability summary | GB‑118 | The data the storage condition rests on. |
| Lot genealogy | GB‑140 | Raw material lot, fill date, container closure lot, and the release signature. |
Regulatory status
This entry sits in the group an FDA advisory committee discussed for the 503A bulk substances list in July 2026. That recommendation is advisory. A proposed rule and then a final rule would be required, and neither has issued. Nothing in that group is compoundable today, so this entry is marked on revision and is not available. No date is stated or implied. Sheet G‑02 carries the full register entry.
Grade Bio is a brand of Mountain Brands LLC. Entity formation is pending and no registration has been filed. Correspondence to jv@gradebio.com or sw@gradebio.com.
Pre‑launch document Entity pending